Table 1.

Clinical pathological parameters of Asian patients with gastrointestinal cancer in this research

Tumor type	Clinical characteristic		N (%)
Liver hepatocellular carcinoma (LIHC)	Age (years)	> 65	36 (22.78)
		≤ 65	122 (77.22)
	Gender	Male	124 (78.48)
		Female	34 (21.52)
	Stage	I–II stage	151 (95.57)
		III–IV stage	7 (4.43)
	Vital status	Alive	114 (72.15)
		Dead	44 (27.85)
Stomach adenocarcinoma (STAD)	Age (years)	> 65	41 (55.41)
		≤ 65	33 (44.59)
	Gender	Male	49 (66.22)
		Female	25 (33.78)
	Stage	I- II stage	43 (58.11)
		III–IV stage	29 (39.19)
		Not reported	2 (2.70)
	Vital status	Alive	54 (72.97)
		Dead	19 (25.68)
		Not reported	1 (1.35)
Esophageal carcinoma (ESCA)	Age (years)	> 65	6 (15.79)
		≤ 65	32 (84.21)
	Gender	Male	35 (92.11)
		Female	3 (7.89)
	Stage	I–II stage	11 (28.95)
		III–IV stage	6 (15.79)
		Not reported	21 (55.26)
	Vital status	Alive	31 (81.58)
		Dead	7 (18.42)
Pancreatic adenocarcinoma (PAAD)	Age (years)	> 65	4 (36.36)
		≤ 65	7 (63.64)
	Gender	Male	5 (45.45)
		Female	6 (54.55)
	Stage	I–II stage	11 (100.00)
		III–IV stage	0 (0.00)
	Vital status	Alive	6 (54.55)
		Dead	5 (45.45)
Colon adenocarcinoma (COAD)	Age (years)	> 65	2 (18.18)
		≤ 65	9 (81.82)
	Gender	Male	8 (72.73)
		Female	3 (27.27)
	Stage	I–II stage	10 (90.91)
		III–IV stage	1 (9.09)
	Vital status	Alive	9 (81.82)
		Dead	2 (18.18)
Cholangiocarcinoma (CHOL)	Age (years)	> 65	2 (66.67)
		≤ 65	1 (33.33)
	Gender	Male	2 (66.67)
		Female	1 (33.33)
	Stage	I–II stage	3 (100.00)
		III–IV stage	0 (0.00)
	Vital status	Alive	1 (33.33)
		Dead	2 (66.67)
Rectum adenocarcinoma (READ)	Age (years)	> 65	0 (0.00)
		≤ 65	1 (100.00)
	Gender	Male	1 (100.00)
		Female	0 (0.00)
	Stage	I–II stage	1 (100.00)
		III–IV stage	0 (0.00)
	Vital status	Alive	1 (100.00)
		Dead	0 (0.00)